Drug Pipeline
15 drugs associated with Adenosine deaminase-deficient severe combined immunodeficiency
| Drug | Phase | Sponsor | |
|---|---|---|---|
Cyclosporine Cyclosporine is a calcineurin inhibitor that inhibits T cell activation. Its binding to the receptor cyclophilin-1 inside cells produces a complex known as cyclosporine-cyclophilin. This complex subsequently inhibits calcineurin, which in turn stops the dephosphorylation as well as the activation of the nuclear factor of activated T cells (NF-AT) that normally cause inflammatory reactions. NF-AT is a transcription factor that promotes the production of cytokines such as IL-2, IL-4, interferon-g | Phase 1 | Fred Hutchinson Cancer Center | ↗ |
Lentiviral Gene Transfer | Phase 1 | National Human Genome Research Institute (NHGRI) | ↗ |
Mycophenolate Mofetil The active metabolite of mycophenolate, mycophenolic acid, prevents T-cell and B-cell proliferation and the production of cytotoxic T-cells and antibodies. Lymphocyte and monocyte adhesion to endothelial cells of blood vessels that normally part of inflammation is prevented via the glycosylation of cell adhesion molecules by MPA. MPA inhibits de novo purine biosynthesis (that promotes immune cell proliferation) by inhibiting inosine 5’-monophosphate dehydrogenase enzyme (IMPDH), with a preferent | Phase 1 | Fred Hutchinson Cancer Center | ↗ |
pivotal | phase1_2 | ||
ADA gene transfer | Phase 2 | Donald B. Kohn, M.D. | ↗ |
Busulfan Busulfan is an alkylating agent that contains 2 labile methanesulfonate groups attached to opposite ends of a 4-carbon alkyl chain. Once busulfan is hydrolyzed, the methanesulfonate groups are released and carbonium ions are produced. These carbonium ions alkylate DNA, which results in the interference of DNA replication and RNA transcription, ultimately leading to the disruption of nucleic acid function. Specifically, its mechanism of action through alkylation produces guanine-adenine intrastra | Phase 2 | Fondazione Telethon | ↗ |
Gene Therapy | Phase 2 | Fondazione Telethon | ↗ |
PEG-ADA ERT | Phase 2 | University of California, Los Angeles | ↗ |
Adagen 2'-deoxyadenosine hydrolytic enzyme; Adenosine hydrolytic enzyme | Phase 3 | Leadiant Biosciences, Inc. | ↗ |
EZN-2279 The ADA-SCID is caused by the presence of mutations in the ADA gene which is responsible for the synthesis of adenosine deaminase. This enzyme is found throughout the body but it is mainly active in lymphocytes. The normal function of adenosine deaminase is to eliminate deoxyadenosine, created when DNA is degraded, by converting it into deoxyinosine. This degradation process is very important as deoxyadenosine is cytotoxic, especially for lymphocytes. Immature lymphocytes are particularly vulner | Phase 3 | Leadiant Biosciences, Inc. | ↗ |
approaches remain | Preclinical | ||
ADA PBSC | unknown | National Human Genome Research Institute (NHGRI) | ↗ |
elapegademase-lvlr The ADA-SCID is caused by the presence of mutations in the ADA gene which is responsible for the synthesis of adenosine deaminase. This enzyme is found throughout the body but it is mainly active in lymphocytes. The normal function of adenosine deaminase is to eliminate deoxyadenosine, created when DNA is degraded, by converting it into deoxyinosine. This degradation process is very important as deoxyadenosine is cytotoxic, especially for lymphocytes. Immature lymphocytes are particularly vulner | unknown | Chiesi Farmaceutici S.p.A. | ↗ |
Strimvelis ADA exogenous gene | unknown | Fondazione Telethon | ↗ |
Transduced Lymphocytes ADA exogenous gene | unknown | National Human Genome Research Institute (NHGRI) | ↗ |